Titre :

Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation.

Auteur(s) :

Ziliotis, M. J. [Auteur]
CH Rambouillet
Vauchy, C. [Auteur]
Centre d'Investigation Clinique de Besançon [Inserm CIC 1431]
Deconinck, E. [Auteur]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) [RIGHT]
Berceanu, A. [Auteur]
Service d'Hématologie [CHRU Besançon]
Büchler, M. [Auteur]
Service de néphrologie et immunologie clinique [CHRU Tours]
Caillard, S. [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Couzi, L. [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Dussol, B. [Auteur]
Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM]
Frimat, L. [Auteur]
Service de Néphrologie [CHRU Nancy]
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Jaulin, J. P. [Auteur]
CHU La Roche-Guyon [AP-HP]
Malvezzi, P. [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Peffault De Latour, R. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Ducloux, D. [Auteur]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) [RIGHT]
Courivaud, C. [Auteur]
Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) [RIGHT]

Titre de la revue :

Kidney International Reports

Nom court de la revue :

Kidney Int Rep

Numéro :

9

Pagination :

1127-1131

Date de publication :

2024-04-01

ISSN :

2468-0249

Mot(s)-clé(s) en anglais :

allogenic
deceased donor
hematopoietic stem cell transplantation
kidney transplantation

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction Hematopoietic stem cell transplantation (HSCT) aims to cure multiple hematologic malignancies, nonmalignant diseases, metabolic disorders, and immune deficiencies. Along with other transplant-related organ ...
Lire la suite >Introduction Hematopoietic stem cell transplantation (HSCT) aims to cure multiple hematologic malignancies, nonmalignant diseases, metabolic disorders, and immune deficiencies. Along with other transplant-related organ toxicities, both acute and chronic kidney disease are common complications of allogeneic HSCT, affecting 10% to 73% and 0% to 60% of patients respectively, depending on the definitions of kidney dysfunction, duration of follow-up and transplant strategies.S1–S4 The proportion of patients with chronic kidney disease who develop end-stage renal disease is approximately 4%. Among those patients who progress to end-stage renal disease and require hemodialysis, mortality is approximately 90%. Few studies have reported successful kidney transplantation (KT) after HSCT in adults; these were mostly small single-center cohorts often with the same donor for HSCT and kidney, and short follow-up.1 ,2 To investigate mortality and the occurrence of severe infections and cancers, we conducted a French multicenter retrospective study of patients who underwent KT, after previous allogeneic HSCT. The details of study methods are shown in the Supplementary Methods. Results Nineteen KT patients with a history of HSCT were identified, of whom 3 had received a kidney from the HSCT donor: the remaining 16 patients were included in the analysis (Table 1 and Supplementary Table S1). Patients were allografted between 1986 and 2006, including 12 patients before 2000, at a median age of 31 (9–55) years (3 pediatric patients and 1 patient older than 45 years). The main indication for HSCT was acute leukemia (n = 11/16: 8 acute myeloid leukemia and 3 acute lymphoblastic leukemia). Three patients had undergone 2 consecutive HSCT (2 relapses and 1 autologous HSCT before allogeneic HSCT). Myeloablative conditioning (n = 14/16) was performed and the graft came from a matched related donor (n = 12/16) in the majority of cases. Baseline nephrologic status was partially or fully available for 9 patients. At the time of HSCT, the 2 most recently allografted patients, the only ones to receive nonmyeloablative conditioning regimen, were already on hemodialysis. Two patients were with stage 2 chronic kidney disease and 5 had no kidney failure.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-06-16T21:00:46Z
2024-08-28T09:27:14Z